Page last updated: 2024-12-07

epidepride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

epidepride: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID86101
CHEMBL ID44237
CHEBI ID125687
SCHEMBL ID8961795
MeSH IDM0175321

Synonyms (18)

Synonym
PDSP2_001484
epidepride
CHEBI:125687
CHEMBL44237 ,
bdbm50008782
epidepride;n-(1-ethyl-pyrrolidin-2-ylmethyl)-5-iodo-2,3-dimethoxy-benzamide
n-(1-ethyl-pyrrolidin-2-ylmethyl)-5-iodo-2,3-dimethoxy-benzamide (epidepride)
n-[[(2s)-1-ethylpyrrolidin-2-yl]methyl]-5-iodo-2,3-dimethoxybenzamide
n-((1-ethyl-2-pyrrolidinyl)methyl)-5-iodo-2,3-dimethoxybenzamide
107188-87-4
n-((1-ethyl-2-pyrrolidinyl)-methyl)-5-iodo-2,3-dimethoxybenzamide
benzamide, n-((1-ethyl-2-pyrrolidinyl)methyl)-5-iodo-2,3-dimethoxy-, (s)-
BRD-K99502674-001-01-5
SCHEMBL8961795
n-[[(2s)-1-ethyl-2-pyrrolidinyl]methyl]-5-iodo-2,3-dimethoxybenzamide
Q27216299
DTXSID00147929
(s)-n-[(1-ethyl-2-pyrrolidinyl)methyl]-5-iodo-2,3-dimethoxy-benzamide

Research Excerpts

Overview

Epidepride is a compound with an affinity in picomolar range for D2/D3 receptors. It may have applications in imaging of receptors in the brain and monitoring pancreatic islet cell grafting.

ExcerptReferenceRelevance
"¹²⁴I-Epidepride is a new radiotracer suitable for extended imaging of dopamine D2/3 receptors and may have applications in imaging of receptors in the brain and monitoring pancreatic islet cell grafting."( ¹²⁴I-Epidepride: a PET radiotracer for extended imaging of dopamine D2/D3 receptors.
Coleman, R; Kant, R; Mukherjee, J; Pandey, S; Venugopal, A,
)
1.16
"Epidepride is a compound with an affinity in picomolar range for D2/D3 receptors. "( Dopamine D(2)/D(3) receptor binding of [(123)I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging.
Chang, KW; Chen, MW; Cheng, KH; Huang, YR; Kuo, WI; Pai, CW, 2014
)
2.1
"Epidepride is a benzamide with high affinity for central D2- and D3-dopamine receptors. "( Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride.
Farde, L; Hall, H; Halldin, C; Hurd, YL; Pauli, S; Sedvall, G, 1996
)
1.95
"Epidepride is a novel benzamide derivative with high affinity for D2 receptors. "( Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
Angelberger, P; Asenbaum, S; Brücke, T; Czech, T; Deecke, L; Kornhuber, J; Luger, A; Pirker, W; Podreka, I; Riedl, M; Rössler, K, 1996
)
1.97
"Epidepride appears to be an excellent ligand for in vivo imaging of dopamine D2 receptors in pituitary adenomas. "( Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
Angelberger, P; Asenbaum, S; Brücke, T; Czech, T; Deecke, L; Kornhuber, J; Luger, A; Pirker, W; Podreka, I; Riedl, M; Rössler, K, 1996
)
1.97
"Epidepride is a benzamide derivative with very high affinity for D2 receptors, which, in its [123I]-labeled form, can be used for SPECT. "( Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease.
Angelberger, P; Asenbaum, S; Brücke, T; Deecke, L; Kornhuber, J; Pirker, W; Podreka, I; Wenger, S, 1997
)
2.13
"Epidepride appears to be a useful SPECT ligand for studying dopamine D2 receptors. "( Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease.
Angelberger, P; Asenbaum, S; Brücke, T; Deecke, L; Kornhuber, J; Pirker, W; Podreka, I; Wenger, S, 1997
)
2.13

Effects

ExcerptReferenceRelevance
"Epidepride has a unique signal-to-noise ratio compared to [(123)I]IBZM but present difficulties for steady-state measurements of striatal regions."( Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion.
Friberg, L; Halldin, C; Knudsen, GM; Lassen, NA; Paulson, OB; Pinborg, LH; Swahn, CG; Videbaek, C, 2000
)
1.25
"Epidepride has a unique signal-to-noise ratio compared to [(123)I]IBZM but present difficulties for steady-state measurements of striatal regions."( Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion.
Friberg, L; Halldin, C; Knudsen, GM; Lassen, NA; Paulson, OB; Pinborg, LH; Swahn, CG; Videbaek, C, 2000
)
1.25

Pharmacokinetics

ExcerptReferenceRelevance
"1 and 1 mg/kg) with a half-life of washout of 55 min."( High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain.
Ansari, MS; Clanton, JA; de Paulis, T; Ebert, MH; Holdeman, KP; Kessler, RM; Manning, RG; Pfeffer, R; Schmidt, DE; Votaw, JR, 1993
)
0.52
" Arterial input curves for IBF and epidepride fit three-exponential models with terminal half-life of 54-76 and 50-59 min, respectively."( Pharmacokinetics of the three radioiodinated dopamine D2 receptor ligands [123I]IBF, [123I]epidepride and [123I]2'-ISP in nonhuman primates.
al-Tikriti, MS; Baldwin, RM; Charney, DS; Hoffer, PB; Laruelle, M; Malison, RT; Seibyl, JP; Sybirska, EH; Zea-Ponce, Y; Zoghbi, SS, 1994
)
0.79
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dimethoxybenzeneAny methoxybenzene that consists of a benzene skeleton substituted with two methoxy groups and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.00040.00000.437510.0000AID65268; AID65269; AID65409
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID65409Inhibition constant against dopamine receptor D2 in rat1993Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2
Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT.
AID35196binding affinity towards alpha-2 adrenergic receptor, using [3H]- atipamezole as radioligand from rat frontal cortex membranes1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Synthesis and in vitro evaluation of 2,3-dimethoxy-5-(fluoroalkyl)-substituted benzamides: high-affinity ligands for CNS dopamine D2 receptors.
AID65268Displacement of [3H]- spiperone from dopamine receptor D2 of striatal membranes without sodium chloride1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Synthesis and in vitro evaluation of 2,3-dimethoxy-5-(fluoroalkyl)-substituted benzamides: high-affinity ligands for CNS dopamine D2 receptors.
AID65269Compound was evaluated for binding affinity towards dopamine receptor D2 in striatal membranes, using [3H]- spiperone as radioligand in the presence of sodium chloride1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Synthesis and in vitro evaluation of 2,3-dimethoxy-5-(fluoroalkyl)-substituted benzamides: high-affinity ligands for CNS dopamine D2 receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (98)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's58 (59.18)18.2507
2000's38 (38.78)29.6817
2010's2 (2.04)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 14.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index14.59 (24.57)
Research Supply Index4.69 (2.92)
Research Growth Index4.09 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (14.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (8.00%)5.53%
Reviews3 (3.00%)6.00%
Case Studies3 (3.00%)4.05%
Observational0 (0.00%)0.25%
Other86 (86.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]